发表或灭亡 v2.
Publish or Perish v2.
机构信息
Division of Hematology and Oncology, Department of Medicine, Columbia University Medical Center, New York New York, USA
出版信息
Oncologist. 2019 Jun;24(6):723-724. doi: 10.1634/theoncologist.2019-0319. Epub 2019 May 7.
Abstract
Communication of clinical trial outcomes is important, but the results of many clinical trials are never published. If we do not publish the results of clinical trials, the lessons learned from those trials will perish. The Oncologist offers a powerful solution through the Clinical Trial Results publishing platform, which uses an established template for authors to easily build a manuscript by simply providing the essential trial data. Through it, every patient's legacy of clinical trial enrollment can matter.
摘要
临床试验结果的交流很重要，但许多临床试验的结果从未发表过。如果我们不发表临床试验的结果，那么从这些试验中获得的经验教训将会消失。《肿瘤学家》通过临床试验结果发布平台提供了一个强大的解决方案，该平台为作者提供了一个经过验证的模板，只需提供必要的试验数据，作者就可以轻松地构建一份手稿。通过这个平台，每一位参与临床试验的患者的贡献都将变得有意义。
相似文献
1
Publish or Perish v2.发表或灭亡 v2.
Oncologist. 2019 Jun;24(6):723-724. doi: 10.1634/theoncologist.2019-0319. Epub 2019 May 7.
2
Publish or perish, publish and perish.不发表就灭亡，发表了也灭亡。
J Adhes Dent. 2014 Apr;16(2):103. doi: 10.3290/j.jad.a31870.
3
[Publish or perish? Challenges in biomedical publishing].
Gac Sanit. 2005 May-Jun;19(3):258-61. doi: 10.1157/13075961.
4
Trial and error.反复试验。
Cancer. 2013 Feb 1;119(3):471-2. doi: 10.1002/cncr.27960.
5
Disclosure of conflicts of interest by authors of clinical trials and editorials in oncology.肿瘤学临床试验和社论作者的利益冲突披露
J Clin Oncol. 2007 Oct 10;25(29):4642-7. doi: 10.1200/JCO.2007.11.2482.
6
Assessing the Eventual Publication of Clinical Trial Abstracts Submitted to a Large Annual Oncology Meeting.评估提交至大型年度肿瘤学会议的临床试验摘要的最终发表情况。
Oncologist. 2016 Mar;21(3):261-8. doi: 10.1634/theoncologist.2015-0516. Epub 2016 Feb 17.
7
Publish or Perish: A Mandate With Negative Collateral Consequences.不发表就出局：一项具有负面附带后果的指令。
Acad Med. 2017 Feb;92(2):140. doi: 10.1097/ACM.0000000000001517.
8
Time to publication of oncology trials and why some trials are never published.肿瘤学试验的发表时间以及部分试验未发表的原因。
PLoS One. 2017 Sep 21;12(9):e0184025. doi: 10.1371/journal.pone.0184025. eCollection 2017.
9
Disclosure of financial conflicts of interest by authors publishing in the Journal of Clinical Oncology.在《临床肿瘤学杂志》上发表文章的作者的财务利益冲突披露。
J Clin Oncol. 2008 Jan 20;26(3):509-10; author reply 510-1. doi: 10.1200/JCO.2007.15.0490.
10
Publish or perish; but what, when, and how?
Am J Orthop (Belle Mead NJ). 2013 Sep;42(9):399-400.
引用本文的文献
1
Accrual, Publication Bias, and the Coronavirus in 2020.2020 年的累积、发表偏倚与冠状病毒。
Oncologist. 2020 Jul;25(7):e1001-e1002. doi: 10.1634/theoncologist.2020-0455. Epub 2020 May 29.
本文引用的文献
1
Trial watch: The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors.试验观察：PD1/PDL1免疫检查点抑制剂的临床试验概况
Nat Rev Drug Discov. 2018 Nov 28;17(12):854-855. doi: 10.1038/nrd.2018.210.
2
Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF).雷莫芦单抗联合帕博利珠单抗治疗既往治疗的晚期或转移性胆道癌患者：非随机、开放标签、I 期试验（JVDF）。
Oncologist. 2018 Dec;23(12):1407-e136. doi: 10.1634/theoncologist.2018-0044. Epub 2018 May 31.
3
Delays in the Publication of Important Clinical Trial Findings in Oncology.肿瘤学中重要临床试验结果发表的延迟。
JAMA Oncol. 2018 Jul 12;4(7):e180264. doi: 10.1001/jamaoncol.2018.0264.
4
Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations.评估胰腺腺癌中错配修复缺陷：挑战与建议。
Clin Cancer Res. 2018 Mar 15;24(6):1326-1336. doi: 10.1158/1078-0432.CCR-17-3099. Epub 2018 Jan 24.
5
Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies.衡量临床试验透明度：对新批准药物和大型制药公司的实证分析
BMJ Open. 2017 Dec 5;7(12):e017917. doi: 10.1136/bmjopen-2017-017917.
6
Time to publication of oncology trials and why some trials are never published.肿瘤学试验的发表时间以及部分试验未发表的原因。
PLoS One. 2017 Sep 21;12(9):e0184025. doi: 10.1371/journal.pone.0184025. eCollection 2017.
7
Discontinuation and non-publication of randomised clinical trials supported by the main public funding body in Switzerland: a retrospective cohort study.瑞士主要公共资助机构支持的随机临床试验的终止和未发表情况：一项回顾性队列研究。
BMJ Open. 2017 Aug 1;7(7):e016216. doi: 10.1136/bmjopen-2017-016216.
8
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.错配修复缺陷可预测实体瘤对程序性死亡受体1（PD-1）阻断疗法的反应。
Science. 2017 Jul 28;357(6349):409-413. doi: 10.1126/science.aan6733. Epub 2017 Jun 8.
9
Barriers towards the publication of academic drug trials. Follow-up of trials approved by the Danish Medicines Agency.学术药物试验发表的障碍。丹麦药品管理局批准的试验随访。
PLoS One. 2017 May 9;12(5):e0172581. doi: 10.1371/journal.pone.0172581. eCollection 2017.
10
Non-Publication Is Common among Phase 1, Single-Center, Not Prospectively Registered, or Early Terminated Clinical Drug Trials.在一期单中心、未进行前瞻性注册或提前终止的临床药物试验中，不发表研究结果的情况很常见。
PLoS One. 2016 Dec 14;11(12):e0167709. doi: 10.1371/journal.pone.0167709. eCollection 2016.
Zotero 插件